Visit Patient Landing Page

You are now leaving our website.

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Continue Cancel
global-banner-bg
global-banner-bg-sm

Most patients with ASCVD need more frequent LDL-C testing1

Frequently testing your patients’ LDL-C is essential to identifying their risk status and
evaluating treatment effectiveness. LDL-C testing may be particularly important after any
change in lipid-lowering therapy.2

Less than 25% of patients at very high risk have their LDL-C tested within 1 year of a heart attack1

LDL-C testing rates in patients at very high risk following their most recent heart attack1

LDL-C testing rates in very high risk patients following post-heart attack hospitalization

Retrospective study using the IQVIA (Longitudinal Access and Adjudication data; LAAD) database of patients with ASCVD at very high risk who had a heart attack (January 2018 to December 2022).

Guidelines Icon
The 2018 AHA/ACC Multisociety cholesterol treatment guidelines recommend2,3

Lipid measurement 4-12 weeks after any change in lipid-lowering therapy*

Repeated every 3-12 months as clinically indicated.

*To assess adherence and response to changes in lifestyle, statin, or nonstatin therapy.

See LDL-C Management recommendations
man-with-headphone
man-with-headphone-sm

Free LDL-C testing is available to your patients†

† Terms and conditions apply. Programs subject to change; quantities may be limited. Visit AttackHeartDisease.com/free-ldl-c-test for details.

LEARN MORE ABOUT TESTING OPTIONS
References: 1. Data on file; Amgen [CV population]; 2023. 2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418. 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73:e285-e350.